treated according to existing guidelines for AIHA and ITP. Nonresponding patients should be given CLL therapy. In CLL patients in need of therapy who do not achieve a complete response (CR) and subsequently develop AIC, and in those with concomitant active CLL and AIC, a front-line “CLL-oriented treatment” approach should be considered. A reasonable approach consists of a short course (2 to 4 weeks) of corticosteroids followed by effective CLL therapy (ie, FCR, bendamustine plus rituximab or etomoxir), depending on the clinical situation (see figure).

**Conflict-of-interest disclosure:** The author declares no competing financial interests.

**REFERENCES**


9. DOI 10.1182/blood.2021010944 © 2021 by The American Society of Hematology

**MYELOID NEOPLASIA**

Comment on Tcheng et al, page 3518

**Break the lifeline of AML cells**

Yoko Tabe1,2 and Marina Konopleva1 1The University of Texas MD Anderson Cancer Center; 2Juntendo University Graduate School of Medicine

In this issue of Blood, Tcheng et al, by zooming in on the role of altered energy metabolism in the pathogenesis and chemoresistance of acute myeloid leukemia (AML) cells and leukemic stem cells (LSCs), implicate the enzyme very-long-chain acyl-CoA dehydrogenase (VLCAD) in supporting fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS) in the mitochondrial metabolism of AML. They further demonstrate preclinical activity of a novel compound inhibiting VLCAD.1

AML cells and LSCs are highly dependent on the production of mitochondrial biomass and rely on FAO2 and OXPHOS3 for survival. Compared with normal hematopoietic cells, they have a lower reserve capacity in their respiratory chain, which renders them susceptible to mitochondrial metabolic stress,4 a promising target for AML therapy. Emerging data highlight FAO as a key metabolic pathway fostering the survival of chemoresistant LSCs. LSCs from patients with relapsed AML acquire a compensatory ability to overcome the loss of amino acid metabolism by increasing FAO.5 This mechanism was recently implicated as causing resistance to azacitidine/venetoclax therapy, a widely used induction regimen for elderly patients with AML.6 In preclinical models, cytarabine arabinoside (AraC)-resistant AML cells displayed increased FAO and OXPHOS, and the FAO inhibitor etomoxir induced an energy shift from high to low OXPHOS, which sensitized these cells to AraC.7 However, the molecular mechanisms of FAO activation in AML cells remained unknown. Thus, the identification of VLCAD by Tcheng et al offers a novel, potentially druggable therapeutic target that is highly selective for AML cells and could be safely translated into clinical trials.

Mitochondrial FAO, the primary catabolic pathway for lipids, generates the reducing compounds NADH and FADH2 for the electron transport chain and provides acetyl-CoA to the tricarboxylic acid cycle to produce adenosine triphosphate (ATP; see figure). The first step in cellular FA utilization is the uptake of long-chain FAs into the cytoplasm, a process facilitated by the scavenger receptor CD36, fatty acid-binding proteins, and transport proteins.7 FAs are then activated in a 2-step reaction, first forming acyl-CoA in the cytoplasm and then breaking down into acetyl-CoA via FAO inside the mitochondria. A rate-limiting step of FAO is catalyzed by carnitine palmitoyl transferase-1 (CPT-1), which conjugates FAs to carnitine, a prerequisite for mitochondrial translocation of FAs from the cytoplasm.6 These FA uptake and consumption mechanisms affect the fate of LSCs, in particular their adaptation to a specialized bone marrow microenvironment and response/resistance to drugs.8 Thus, CD36 and CPT-1 have been considered potential pharmacological targets for FAO inhibition in AML. A CD36 neutralizing antibody has been shown to impair metastasis of human melanoma and breast cancer cells.9 Inhibition of CPT-1 causes mitochondrial damage and induces cell death in primary AML cells.10

The intramitochondrial FAO enzyme VLCAD, identified by Tcheng et al, catalyzes the first intramitochondrial step of long-chain FAOs. They further identified a polyhydroxylated fatty alcohol with a terminal alkyne known as avocadyne (16-heptadecyne-1,2,4-triol; AYNE) as a potential small-molecule VLCAD inhibitor in a respirometry-based screening. By using both VLCAD knockdown and the novel pharmacological inhibitor AYNE, the research team convincingly demonstrated reduction of mitochondrial respiration caused by FAO alteration, leading to reduced ATP production in AML cells, despite moderate upregulation of glycolysis,
The discovery of VLCAD as a novel, potentially druggable target in AML cells emphasizes the role of mitochondrial metabolism in AML and prompts further in-depth exploration of the metabolic dependencies of AML and their potential for therapeutic translation. Several important questions await further study. Are all AMLs FAO dependent, or is this phenomenon genotype conferred? Is a therapeutic window achievable with chronic FAO inhibition, given cardiomyopathy concerns that arise in acute murine deletion experiments, or is intermittent blockade of the pathway sufficient to induce death of malignant cells and spare normal cells? Given the heterogeneity and multiclonal nature of AML, would blocking just one arm of the multifaceted metabolic machinery produce antileukemia efficacy before metabolic adaptation? Or should the focus shift toward targeting the residual AML cells and LSCs that survive chemotherapeutic stress and have been shown to have specific metabolic vulnerabilities?

Despite these unknowns, Tcheng et al have aided the field by providing a previously missing link in our understanding of how AML subverts the cell’s powerful energy-generating machinery to its favor, thereby creating a metabolic Achilles heel that can be exploited therapeutically.

Their comprehensive biochemical and mechanistic analyses targeting VLCAD in FAO offer the possibility of future combinatorial therapeutic strategies that could facilitate the elimination of AML cells and LSCs while reducing on-target, off-tumor toxicity.

Conflict-of-interest disclosure: Y.T. reports grants and other support from Sysmex, Kohjin Bio, and Roche Diagnostics. M.K. reports grants and other support outside the submitted work from AbbVie, F. Hoffman-La Roche, Stemline Therapeutics, Forty-Seven, and Genentech; grants outside the submitted work from Eli Lilly, Collectes, Calithera, Ablynx, Agios, Ascentage, AstraZeneca, Rafael Pharmaceutical, and Sanofi; and other support from Reata Pharmaceuticals and Janssen. In addition, M.K. has patents US 7,795,305 B2 “CDDO-compounds and combination therapies thereof” with royalties paid to Reata Pharmaceuticals; “Combination therapy with a mutant IDH1 inhibitor and a BCL-2” licensed to Eli Lilly, and 62/993,166 “Combination of a MCL-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof” pending to Novartis.

REFERENCES
8. Tabe Y, Yamamoto S, Saitoh K, et al. Bone Marrow Adipocytes Facilitate Fatty Acid
Bone and blood: IL-19 to the rescue

Paola Divieti Pajevic | Boston University School of Dental Medicine

In this issue of Blood, Xiao et al1 identified interleukin 19 (IL-19) as a potent cytokine capable of promoting expansion and proliferation of neutrophils. Neutropenia is a common consequence of chemotherapy, and there are currently very few and limited treatments available. Surprisingly, osteocytes, the bone cells deeply embedded in the mineralized matrix, are the major source of IL-19, placing these cells, once again, on the list of important regulators of hematopoiesis.2,3 Osteocytes primary function is to control skeletal homeostasis through 2 secreted proteins: sclerostin,4,5 a Wnt inhibitor that suppresses bone formation, and Rankl, a cytokine required for osteoclastogenesis.6 In this article, Xiao et al used a combination of genetically modified mice and in vitro models to provide evidence that osteocytes are also the main source of IL-19, a cytokine that promotes the expansion of neutrophils.

The article presents 2 major advancements in the field: the identification of IL-19 as a regulator of neutrophils maturation and proliferation and that the osteocytes (and possibly late mature osteoblasts) are the major source of this cytokine.

IL-19 functions as an anti-inflammatory and proangiogenic factor.7 It belongs to a subfamily that includes IL-20, IL-22, IL-14, and IL-26, and it signals by binding to a receptor complex consisting of an heterodimer of IL-20Rα and IL-20Rβ promoting a T helper 2 regulatory T-cell8 response in a variety of disease contexts.

In this article, the authors first analyzed the role of mechanistic target of rapamycin complex 1 (mTORC1) in osteocytes by generating mice where the expression of this protein was increased, by deleting its inhibitor, tuberous sclerosis complex protein 1 (TSC1), or decreased, by deleting the upstream activator Rheb. mTORC1 regulates both cell proliferation in response to metabolic challenges and myeloid differentiation.9 When mTORC1 is activated in Dmp1-expressing cells, neutrophils are significantly increased, whereas mTORC1 inhibition induces neutropenia. The in vivo studies are followed by an extensive in vitro characterization of the relative contribution of different cell types, including osteocytes, osteoclasts, endothelial cells, bone marrow stromal cells, lymphocytes, and monocytes. Strikingly, only primary osteocytes recapitulate the in vivo phenotype. Next, the authors identify IL-19 as the factor driving the hematopoietic phenotype. As predicted, IL-19 administration rescues the neutropenia present in the Dmp1-TSC1 knockout (KO) mice, whereas intramedullary administration of IL-19-neutralizing antibody corrects the neutrophilia in the Dmp1-Rheb KO animals. Last, and possibly most importantly, administration of IL-19 protects wild-type mice from neutropenia induced by both chemotherapy and radiation, demonstrating the therapeutic efficacy of this cytokine. It remains unknown whether IL-19 has additional effects on other organs or tissues, but its potential application in neutropenic states is undoubted. Additional studies will be needed to determine whether factors known to control osteocytes also regulate IL-19 synthesis and secretion and whether this cytokine has additional skeletal and other organ effects. Tissue distribution and downstream signals have only been partially elucidated, and a clearer picture of the function of this cytokine is required. One puzzling finding of this paper is that the phenotype is present only in Dmp1-TSC1 KO animals, and not in mice in which Tsc1 is ablated in osteoprogenitors (Osx-TSC1 KO) or osteoblasts (Ocn-TSC1 KO). This suggests that Tsc1 expression in these cells (osteoprogenitors and osteoblasts) prevents the expansion of neutrophils present in Dmp1-Tsc1 KO animals. One possible explanation is that when Tsc1 is ablated from early osteoprogenitors and osteoblasts, the hematopoietic stem cell niche is altered and can no longer support the expansion of granulocyte monophasate. Further characterization of the hematopoietic phenotype of Osx and Oc-Tsc1 mice will be needed to try to explain this conundrum.

Regardless of these questions, this study is a breakthrough in the development of novel therapeutic interventions to treat neutropenic states.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES

7. Leigh T, Scalio RG, Autieri MV. Resolution of inflammation in immune and nonimmune cells.